Dette er hentet fra prospektet og burde leses, har sagt det før men kan godt si det igjen.

Her kan det smelle noe så inn i granskauen.

The competitive landscape for PCI Biotech’s fimaVACC technology
Therapeutic cancer vaccination has been a growing field with a substantial development pipeline and high
expected market growth35. Several late stage failures due to poor efficacy have however highlighted the need
for improved vaccination technologies with increased immune responses36. fimaVACC is a novel Cytotoxic T-Cell
(CTL) induction technology with an innovative mode of action through CTL induction by enhanced MHC class I
antigen presentation in dendritic cells and macrophages. CTL induction is a key factor for the efficacy of
therapeutic vaccines. PCI Biotech has compelling pre-clinical data showing significant immune-potentiating
effects, which in addition works in strong synergy with other state-of-the-art vaccine technologies in clinical
development, and translates into therapeutic effect in disease models. Initial data from the ongoing Phase I study
in healthy volunteers on overall T-cell responses indicate that vaccination with well-tolerated doses of fimaVACC
enhance cellular immune responses important for therapeutic effect of vaccines. The data also suggest that
fimaVACC trigger early T-cell responses and provide high response rates, which are two highly sought-after
features of vaccination platforms.

Mulige bruksområder:

1. Fight against cancer with immunotherapy.
2. Therapeutic and prophylactic vaccination for other important diseases.
3. Treatment of chronic viral diseases.
4. Tuberculosis.
5. Malaria.
6. Prophylactic vaccines for important infectious diseases.

++++ there are also many other potential target diseases for fimaVACC based prophylactic vaccination.


The active ingredient in fimaVACC (fimaporfin; TPCS2a) is a stable small molecule with broad applicability. All these
attributes makes the fimaVACC technology a potential future important player in the fight against cancer with
immunotherapy. In addition to the use in therapeutic vaccination for cancer, fimaVACC has the potential to be
used for both therapeutic and prophylactic vaccination for other important diseases. E.g., fimaVACC is very well
suited for therapeutic vaccination for the treatment of chronic viral diseases (e.g. Hepatitis B), and possibly also
for therapeutic vaccination for tuberculosis. Furthermore, the fimaVACC technology also has a clear potential to
contribute to the development of new prophylactic vaccines for important infectious diseases lacking effective
vaccines. Prominent examples are malaria and tuberculosis, but there are also many other potential target
diseases for fimaVACC based prophylactic vaccination.

Helt rått :)